Top in hem/onc: Financial management tips; breast cancer treatment strategies

In the latest installment of Residency to Retirement, wealth management experts discussed how physicians can safeguard their bond investments. It was the top story in hematology/oncology last week.

The second top story was about new research that showed certain women with luminal A breast cancer can forgo radiotherapy after breast-conserving surgery.

Read these and more top stories in hematology/oncology below:

Bonds are losing money: Actions to take

The Bloomberg U.S. Aggregate Bond Index experienced its worst-performing quarter in more than 40 years, losing 5.93% from January to March. Read more.

Some older women with luminal A breast cancer can safely forgo radiotherapy, study shows

Patients aged 55 years or older with low-grade luminal A breast cancer who receive endocrine therapy can safely avoid radiotherapy after breast-conserving surgery, according to a prospective study presented at ASCO Annual Meeting. Read more.

Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset

Dostarlimab, an anti-PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate among a small cohort of patients with mismatch repair-deficient locally advanced rectal cancer, phase 2 study results showed. Read more.

Investigational CAR-T shows promise for advanced multiple myeloma

A single dose of a novel chimeric antigen receptor T-cell therapy induced objective response among all treated patients with relapsed or refractory multiple myeloma, according to study results. Read more.

Trastuzumab deruxtecan extends survival in HER2-low metastatic breast cancer

Trastuzumab deruxtecan significantly extended PFS and OS among patients with HER2-low metastatic breast cancer, regardless of hormone receptor status, compared with standard of care therapy. Read more.